๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

BioMoleculesAlive.org: The biochemistry and molecular biology digital library update

โœ Scribed by Paul A. Craig


Publisher
The American Society for Biochemistry and Molecular Biology
Year
2003
Tongue
English
Weight
32 KB
Volume
31
Category
Article
ISSN
1470-8175

No coin nor oath required. For personal study only.

โœฆ Synopsis


BioMoleculesAlive.org is a collection of digital resources sponsored by the American Society for Biochemistry and Molecular Biology. It is part of a larger effort called the BioSciEdNet (BEN) initiative (www.biosciednet.org). The collection will include resources in five areas: software, visual resources, curriculum resources, reviews, and articles from Biochemistry and Molecular Biology Education.

Efforts on the web interface, database design, and tools and guidelines for submission to BioMoleculesAlive.org are ongoing. We hope to be open for submissions by April 2003. Please plan to attend our session at the American Society for Biochemistry and Molecular Biology (ASBMB) meeting in San Diego (12 noon on Saturday, April 12, 2003) where you will be able to hear about our progress and to meet some of the members of the steering committee. In the meantime, we have identified several examples of the types of resources we are seeking in the areas of molecular visualization, software, and curriculum. Please check out these exemplary websites for ideas on BioMolecules-Alive.org submissions of your own.


๐Ÿ“œ SIMILAR VOLUMES


Biochemistry and molecular biology, four
โœ Qiuyu Wang; Chris Smith ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› The American Society for Biochemistry and Molecula ๐ŸŒ English โš– 29 KB ๐Ÿ‘ 2 views
Update on the molecular biology of malig
โœ Amie Y. Lee; Dan J. Raz; Biao He; David M. Jablons ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 166 KB

## Abstract Malignant mesothelioma (MM) is a highly aggressive tumor with a very poor prognosis. The disease is largely unresponsive to conventional chemotherapy or radiotherapy, and most patients die within 10โ€“17 months of the first symptoms. Novel, more effective therapeutic strategies are needed